Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SRPT

SRPT - Sarepta Therapeutics Inc Stock Price, Fair Value and News

$21.33-0.84 (-3.79%)
Market Closed

81/100

SRPT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

81/100

SRPT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$31.7

Target 3M

$24.09

Target 6M

$27.47

SRPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SRPT Price Action

Last 7 days

-0.2%

Last 30 days

-2.2%

Last 90 days

-8.3%

Trailing 12 Months

-81.8%

SRPT RSI Chart

SRPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SRPT Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-8.23

Price/Sales (Trailing)

0.93

EV/EBITDA

-8.64

Price/Free Cashflow

-5.86

SRPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$31.7

Target 3M

$24.09

Target 6M

$27.47

SRPT Fundamentals

SRPT Revenue

Revenue (TTM)

2.4B

Rev. Growth (Yr)

-14.52%

Rev. Growth (Qtr)

-34.65%

SRPT Earnings

Earnings (TTM)

-271.5M

Earnings Growth (Yr)

-635.38%

Earnings Growth (Qtr)

-191.39%

SRPT Profitability

EBT Margin

-10.45%

Return on Equity

-20.57%

Return on Assets

-7.77%

Free Cashflow Yield

-17.05%

SRPT Investor Care

Shares Dilution (1Y)

9.70%

Diluted EPS (TTM)

-2.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20252.2B2.5B2.4B0
20241.4B1.5B1.6B1.9B
2023975.7M1.0B1.1B1.2B
2022765.8M835.2M876.0M933.0M
2021573.4M600.1M645.6M701.9M
2020407.5M450.2M495.1M540.1M
2019323.4M344.6M365.1M380.8M
2018202.8M241.4M273.9M301.0M
201737.9M70.3M102.7M154.6M
20165.0M5.2M5.3M5.4M
20150004.9M
201415.8M15.5M12.4M9.8M
201330.6M22.3M18.9M14.2M
201243.9M43.5M43.6M37.3M
201142.5M50.1M48.9M47.0M
2010021.5M25.5M29.4M
200900017.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Sarepta Therapeutics Inc

SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEsarepta.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES1162

Sarepta Therapeutics Inc Frequently Asked Questions

SRPT is the stock ticker symbol of Sarepta Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Sarepta Therapeutics Inc is 2.24 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SRPT's fair value in chart for subscribers.

The fair value guage provides a quick view whether SRPT is over valued or under valued. Whether Sarepta Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sarepta Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRPT.

As of Wed Jan 28 2026, SRPT's PE ratio (Price to Earnings) is -8.23 and Price to Sales (PS) ratio is 0.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRPT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Sarepta Therapeutics Inc has provided 0.06 (multiply by 100 for percentage) rate of return.